These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 15736529)

  • 21. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.
    Vanlerberghe V; Diap G; Guerin PJ; Meheus F; Gerstl S; Van der Stuyft P; Boelaert M
    Trop Med Int Health; 2007 Feb; 12(2):274-83. PubMed ID: 17300636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
    Singh N; Chatterjee M; Sundar S
    Parasit Vectors; 2014 Dec; 7():596. PubMed ID: 25515494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Miltefosine in a case of visceral leishmaniasis with HIV co-infection; and rising incidence of this disease in India.
    Thakur CP; Sinha PK; Singh RK; Hassan SM; Narain S
    Trans R Soc Trop Med Hyg; 2000; 94(6):696-7. PubMed ID: 11198660
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of visceral leishmaniasis: a review of current treatment practices.
    Marty P; Rosenthal E
    Expert Opin Pharmacother; 2002 Aug; 3(8):1101-8. PubMed ID: 12150689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Visceral leishmaniases].
    Piarroux R; Bardonnet K
    Rev Prat; 2001 Dec; 51(19):2104-7. PubMed ID: 11842729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
    Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of visceral leishmaniasis: Indian perspective.
    Agrawal S; Rai M; Sundar S
    J Postgrad Med; 2005; 51 Suppl 1():S53-7. PubMed ID: 16519257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
    Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India.
    Patra P; Guha SK; Maji AK; Saha P; Ganguly S; Chakraborty A; Kundu PK; Sarker S; Ray K
    Indian J Pharmacol; 2012; 44(4):500-3. PubMed ID: 23087513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
    Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
    Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
    Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
    Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.
    Pérez-Jacoiste Asín MA; Carrasco-Antón N; Fernández-Ruiz M; San Juan R; Alonso-Moralejo R; González E; Andrés A; López-Medrano F; Aguado JM
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27768239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Miltefosine for Indian visceral leishmaniasis.
    Roca B
    N Engl J Med; 2003 Feb; 348(9):857-8; author reply 857-8. PubMed ID: 12608397
    [No Abstract]   [Full Text] [Related]  

  • 35. [First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France].
    Minodier P; Robert S; Noël G; Blanc P; Retornaz K; Garnier JM
    Arch Pediatr; 2005 Jul; 12(7):1102-8. PubMed ID: 15964525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
    Abongomera C; Diro E; de Lima Pereira A; Buyze J; Stille K; Ahmed F; van Griensven J; Ritmeijer K
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006527. PubMed ID: 29799869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India.
    Bhattacharya SK; Jha TK; Sundar S; Thakur CP; Engel J; Sindermann H; Junge K; Karbwang J; Bryceson AD; Berman JD
    Clin Infect Dis; 2004 Jan; 38(2):217-21. PubMed ID: 14699453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.
    Murray HW
    Expert Rev Anti Infect Ther; 2004 Apr; 2(2):279-92. PubMed ID: 15482193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistance in Indian visceral leishmaniasis.
    Sundar S
    Trop Med Int Health; 2001 Nov; 6(11):849-54. PubMed ID: 11703838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
    Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A
    Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.